Journal article
High-dose docosahexaenoic acid supplementation of preterm infants: Respiratory and allergy outcomes
BJ Manley, M Makrides, CT Collins, AJ McPhee, RA Gibson, P Ryan, TR Sullivan, PG Davis
Pediatrics | Published : 2011
Abstract
BACKGROUND: Docosahexaenoic acid (DHA) has been associated with downregulation of inflammatory responses. OBJECTIVE: To report the effect of DHA supplementation on long-term atopic and respiratory outcomes in preterm infants. METHODS: This study is a multicenter, randomized controlled trial comparing the outcomes for preterm infants <33 weeks' gestation who consumed expressed breast milk from mothers taking either tuna oil (high-DHA diet) or soy oil (standard-DHA) capsules. Data collected included incidence of bronchopulmonary dysplasia (BPD) and parental reporting of atopic conditions over the first 18 months of life. RESULTS: Six hundred fifty-seven infants were enrolled (322 to high-DHA d..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
The DINO trial was supported by a grant from the National Health and Medical Research Council of Australia (ID 250322). Treatment and placebo capsules were donated by Clover Corporation, and infant formula was donated by Mead Johnson Nutritionals and Nutricia Australia. Research fellowships were from the National Health and Medical Research Council of Australia (Drs Makrides, Gibson, and Davis). None of the funding bodies or companies had any role in study design, data collection, analyses, or manuscript preparation.